Lacosamide Accord (Lacosamide)

Lacosamide enhances the slow inactivation of voltage‑gated sodium channels in neuronal membranes. This stabilises the inactive state of the channels, limiting repetitive firing of hyper‑excitable neurons and thereby reducing the likelihood of seizure generation.

The specific dose of lacosamide is determined by the prescribing clinician based on the individual’s clinical condition, response, and any concomitant therapies. Dosage adjustments are made according to therapeutic response and tolerability, and the prescriber provides the exact regimen.

Safety data for lacosamide during pregnancy and lactation are limited. It is generally advised to avoid use unless the potential benefit to the mother outweighs any possible risk to the fetus or infant. Women who are pregnant, planning pregnancy, or breastfeeding should discuss alternatives with their healthcare provider.

To order Lacosamide Accord, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request verification of trade or institutional credentials before providing pricing, availability, shipping details and any necessary import documentation.

Compared with older sodium‑channel blockers such as carbamazepine, lacosamide selectively enhances slow inactivation rather than fast inactivation, which may result in a different side‑effect profile and fewer drug‑interaction concerns. Unlike broad‑spectrum agents like levetiracetam, lacosamide’s mechanism is more targeted, offering an alternative for patients who do not respond to or tolerate other antiepileptics.

Lacosamide Accord tablets should be stored at temperatures below 25 °C. Keep the product in its original packaging, protect it from moisture and direct light, and store it in a dry place away from excessive heat to maintain potency throughout its shelf life.

Lacosamide Accord is taken orally as a tablet with a glass of water. It may be taken with or without food, according to the prescriber’s instructions. Patients should follow the dosing schedule provided by their healthcare professional and not alter the regimen without medical advice.

Serious risks include cardiac conduction abnormalities such as PR‑interval prolongation or atrioventricular block, which may require ECG monitoring, and rare severe skin reactions like Stevens‑Johnson syndrome. Additionally, any new or worsening mood changes, including suicidal thoughts, should be reported promptly to a healthcare professional.

Lacosamide should be avoided in patients with known hypersensitivity to the drug or any of its excipients. Caution is also advised for individuals with significant cardiac conduction disorders, severe renal impairment, or those taking medications that strongly affect its metabolism without appropriate monitoring.